Volibo 0.2 Tablet 15: Uses, Side Effects, Price & Substitutes

About Volibo 0.2 Tablet 15

Volibo 0.2 Tablet 15 is a medicine used to help control blood sugar levels in adults with type 2 diabetes. It is particularly effective at controlling post-meal spikes in blood sugar, ensuring steadier glucose levels throughout the day alongside diet and regular exercise.

It contains voglibose, an alpha-glucosidase inhibitor. Take it just before each main meal as prescribed. Continue taking it regularly as advised by your doctor.

A balanced diet with controlled carbohydrate distribution, regular physical activity, maintaining a healthy weight, and monitoring blood sugar levels support optimal diabetes management alongside this medicine.

Before taking this medicine, tell your doctor if you have any history of intestinal blockage, severe bowel disease, or severe kidney impairment. If you experience low blood sugar while taking this medicine with other diabetes drugs, treat it with pure glucose rather than table sugar. Contact your doctor if you develop severe or persistent stomach pain.

Frequently Asked Questions (FAQs)

What is Volibo 0.2 Tablet 15 used for?

Volibo 0.2 Tablet 15 is used to treat type 2 diabetes mellitus when diet and exercise alone cannot control blood sugar levels. As an alpha-glucosidase inhibitor, it slows down carbohydrate breakdown in the gut, especially after meals, reducing post-prandial glucose spikes and helping prevent complications.

What is Volibo 0.2 Tablet 15 used for?

Volibo 0.2 Tablet 15 is used to manage type 2 diabetes mellitus. As an alpha-glucosidase inhibitor, it helps control blood sugar levels, particularly after meals, when diet and exercise alone are not enough. In addition to managing blood glucose, it also helps prevent long-term complications of uncontrolled diabetes, such as kidney damage, nerve problems, blindness, and cardiovascular diseases.

What does Volibo 0.2 Tablet 15 do?

Volibo 0.2 Tablet 15 works by slowing down the digestion of carbohydrates, reducing the rise in blood sugar levels after meals.

How should I use Volibo 0.2 Tablet 15?

You should take Volibo 0.2 Tablet 15 orally just before each main meal. It's important to swallow the tablet whole with a glass of water.

Can I take other diabetes medicines with Volibo 0.2 Tablet 15?

Yes, you can take Volibo 0.2 Tablet 15 with other diabetes medicines like insulin and metformin, but always consult your doctor for proper dosage adjustments.

What should I do if I miss a dose of Volibo 0.2 Tablet 15?

If you miss a dose, take it as soon as you remember unless it's nearly time for your next scheduled dose. Never double up on doses to compensate for the missed one.

Are there any side effects of using Volibo 0.2 Tablet 15?

Common side effects include abdominal pain, diarrhoea, and flatulence, which usually subside over time. Consult a doctor if you experience any persistent side effects.

Can pregnant or breastfeeding women take Volibo 0.2 Tablet 15?

Exercise caution if you are taking Volibo 0.2 Tablet 15 during pregnancy or while breastfeeding. Always consult your doctor before taking this medicine.

References

National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 444020, Voglibose. https://pubchem.ncbi.nlm.nih.gov/compound/Voglibose
Dabhi, A. S., Bhatt, N. R., & Shah, M. J. (2013). Voglibose: an alpha glucosidase inhibitor. Journal of clinical and diagnostic research: JCDR, 7(12), 3023–3027. https://doi.org/10.7860/JCDR/2013/6373.3838
DrugBank Online. (2021, Jun 19). Voglibose. https://go.drugbank.com/drugs/DB04878
Matsumoto, K., Yano, M., Miyake, S., Ueki, Y., Yamaguchi, Y., Akazawa, S., & Tominaga, Y. (1998). Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes care, 21(2), 256–260. https://doi.org/10.2337/diacare.21.2.256
Göke, B., Fuder, H., Wieckhorst, G., Theiss, U., Stridde, E., Littke, T., Kleist, P., Arnold, R., & Lücker, P. W. (1995). Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion, 56(6), 493–501. https://doi.org/10.1159/000201282
Kurebayashi, S., Watada, H., Tanaka, Y., Kawasumi, M., Kawamori, R., & Hirose, T. (2006). Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study. Endocrine journal, 53(2), 213–217. https://doi.org/10.1507/endocrj.53.213
Saito, N., Sakai, H., Suzuki, S., Sekihara, H., & Yajima, Y. (1998). Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients. The Journal of international medical research, 26(5), 219–232. https://doi.org/10.1177/030006059802600501

Disclaimer

We, at Truemeds make a diligent attempt to deliver accurate, expert- drafted and thoroughly reviewed medicine related information to our consumers. However, it should, by no means, be considered a substitute for prescription from a certified doctor or a trustworthy doctor-patient relationship. In fact we detest any form of self medication without expert advice. The sole purpose of the information on our portal is to educate our consumers, which helps improve the communication between a doctor and a patient. The information by no means is complete in its entirety and should not be used to diagnose or treat any medical condition. No amount of information can replace the experience and expertise of a doctor, therefore his/her advice always holds priority and should be followed appropriately.